Bridget E. Bunner

Array ( [id] => 14227313 [patent_doc_number] => 20190125829 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => METHOD FOR PREVENTING OBESITY-INDUCED FATTY LIVER BY INHIBITING KCTD17 [patent_app_type] => utility [patent_app_number] => 16/096573 [patent_app_country] => US [patent_app_date] => 2017-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944717 [patent_doc_number] => 10208114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Methods of treating liver conditions using Notch2 antagonists [patent_app_type] => utility [patent_app_number] => 15/496516 [patent_app_country] => US [patent_app_date] => 2017-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 45 [patent_figures_cnt] => 96 [patent_no_of_words] => 24453 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15496516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17512600 [patent_doc_number] => 11291718 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-05 [patent_title] => Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein [patent_app_type] => utility [patent_app_number] => 16/341415 [patent_app_country] => US [patent_app_date] => 2017-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 12220 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16341415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977600 [patent_doc_number] => 20170281754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'Compositions and Methods for Enhanced Innate Immunity' [patent_app_type] => utility [patent_app_number] => 15/476723 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 13463 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15476723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14043527 [patent_doc_number] => 20190077870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => ENGINEERED TRAIL FOR CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/084447 [patent_app_country] => US [patent_app_date] => 2017-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14435753 [patent_doc_number] => 20190175748 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-13 [patent_title] => COMBINATION OF AN IMMUNE CHECKPOINT MODULATOR AND A COMPLEX COMPRISING A CELL PENETRATING PEPTIDE, A CARGO AND A TLR PEPTIDE AGONIST FOR USE IN MEDICINE [patent_app_type] => utility [patent_app_number] => 16/084170 [patent_app_country] => US [patent_app_date] => 2017-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59866 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16084170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870843 [patent_doc_number] => 20190031762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => POSTERIOR OCULAR FIBROSIS INHIBITION BY ANTAGONIZING PLACENTAL GROWTH FACTOR [patent_app_type] => utility [patent_app_number] => 16/077013 [patent_app_country] => US [patent_app_date] => 2017-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16077013 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422631 [patent_doc_number] => 10316105 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Anti-TIE2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 15/445563 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 17175 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15445563 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18247615 [patent_doc_number] => 11604194 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-03-14 [patent_title] => Method for detecting castration-resistant prostate cancer and detection reagent [patent_app_type] => utility [patent_app_number] => 16/080577 [patent_app_country] => US [patent_app_date] => 2017-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11532 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16080577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16222733 [patent_doc_number] => 20200247849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => PEPTIDE AGONISTS AND ANTAGONISTS OF TLR4 ACTIVATION [patent_app_type] => utility [patent_app_number] => 15/998974 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15998974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851679 [patent_doc_number] => 20170226168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'CELL-PERMEABLE (ICP)-SOCS3 RECOMBINANT PROTEIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/432662 [patent_app_country] => US [patent_app_date] => 2017-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 106 [patent_figures_cnt] => 106 [patent_no_of_words] => 40632 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15432662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11662498 [patent_doc_number] => 20170151204 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-01 [patent_title] => 'USE OF LEUKOTRIENE B4 IN COMBINATION WITH A TOLL-LIKE RECEPTOR LIGAND, A RIG-I-LIKE RECEPTOR LIGAND, OR A NOD-LIKE RECEPTOR LIGAND TO ENHANCE THE INNATE IMMUNE RESPONSE' [patent_app_type] => utility [patent_app_number] => 15/429872 [patent_app_country] => US [patent_app_date] => 2017-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 11370 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15429872 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929653 [patent_doc_number] => 20190048342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => CROSS-REGULATION OF TYPE I INTERFERON SIGNALING PATHWAYS [patent_app_type] => utility [patent_app_number] => 16/075661 [patent_app_country] => US [patent_app_date] => 2017-02-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14360207 [patent_doc_number] => 10301391 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-28 [patent_title] => BCMA and CD3 bispecific T cell engaging antibody constructs [patent_app_type] => utility [patent_app_number] => 15/422619 [patent_app_country] => US [patent_app_date] => 2017-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 19 [patent_no_of_words] => 45611 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11879653 [patent_doc_number] => 09750808 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-09-05 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 15/418460 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13764 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11670038 [patent_doc_number] => 20170158759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/418469 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13552 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11844607 [patent_doc_number] => 09732152 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-15 [patent_title] => 'Formulation of human antibodies for treating TNF-alpha associated disorders' [patent_app_type] => utility [patent_app_number] => 15/418465 [patent_app_country] => US [patent_app_date] => 2017-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13757 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15418465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627298 [patent_doc_number] => 20170137487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES' [patent_app_type] => utility [patent_app_number] => 15/411649 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 31756 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12259301 [patent_doc_number] => 20180078496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'ARTICLE OF MANUFACTURE COMPRISING AFLIBERCEPT OR ZIV-AFLIBERCEPT' [patent_app_type] => utility [patent_app_number] => 15/409377 [patent_app_country] => US [patent_app_date] => 2017-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15293 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15409377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11729318 [patent_doc_number] => 20170190761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-06 [patent_title] => 'TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR' [patent_app_type] => utility [patent_app_number] => 15/404749 [patent_app_country] => US [patent_app_date] => 2017-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 46725 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15404749 [rel_patent_id] =>[rel_patent_doc_number] =>)